. 2019 Feb 3;8(2):177. doi: 10.3390/jcm8020177

Table 2.

Correlation of plasma levels of LDL-C, L5, L5%, or LOX-1 expression with the extent of subclinical atherosclerosis and 10-year CVD risk (QRISK-2) scores in RA patients (n = 64).

	Plasma LDL-C Levels	LDLR Expression	Plasma L5%	Plasma L5 Levels	LOX-1 Expression
Right ccIMT, mm	0.217	0.150	0.537 ^b	0.611 ^b	0.457 ^b
Left ccIMT, mm	0.245	0.223	0.457 ^b	0.540 ^b	0.507 ^b
QRISK-2 scores	0.072	0.244	0.256 ^a	0.278 ^a	0.339 ^a
Framingham score (%)	0.160	0.336^a	0.107	0.188	0.251
Atherogenic index	0.635 ^b	0.294 ^a	−0.024	0.281 ^a	0.318 ^a
LDL-C levels	-	0.181	−0.107	0.298 ^a	0.117
LDLR expression	0.181	-	0.102	0.182	0.298 ^a
Plasma L5%	−0.107	0.102	-	0.895^b	0.497 ^b
Plasma L5 levels	0.298 ^a	0.182	0.895 ^b	-	0.588 ^b
LOX-1 expression	0.117	0.298 ^a	0.497 ^b	0.588 ^b	-
Body mass index	0.056	0.108	0.300 ^a	0.317 ^a	0.458 ^b
DAS28 at entry	−0.225	−0.015	0.361 ^b	0.254 ^a	0.166

^ap < 0.05 and ^b p < 0.01, determined by using the nonparametric Spearman’s correlation test. Atherogenic index corresponds to the ratio of total cholesterol/high-density lipoprotein cholesterol. RA: Rheumatoid arthritis; ccIMT: Common carotid artery intima-media thickness; LDLR: LDL-C receptor; LOX-1: Lectin-like oxidized low-density lipoprotein recptor-1; DAS28: Disease activity score for 28-joints.